The Backlog Finally Converts, but the Share Price Has Already Moved On
Key Takeaways
- Emerson delivered the acceleration we wanted to see: underlying sales grew 6%, including 3% volume, against a ~5% guide. Intelligent Devices returned to growth and adjusted segment EBITA margin reached 28.5%, above the ~28% plan.
- Cash has caught up substantially. Quarterly free cash flow of $1,323M rose 36%; excluding an $82M tariff refund, growth was still about 28%. Tax payments shifted into Q4, so the recovery is stronger than our prior forecast but not wholly recurring.
- Power and semiconductor demand support another year of earnings growth, while China and Europe are becoming smaller drags. Software ACV remains at 9% growth, leaving the promised 10%-plus exit rate and the renewal reversal for Q4.
- Rating: Maintaining Hold. The prior operating upgrade condition is substantially fulfilled, but at $162.47 the shares offer only about 5.5% total return to our new $169.20 central value. Our twelve-month fair-value range rises to $166–$173, primarily as valuation moves to FY27 earnings.
Results vs. Consensus
The decisive improvement is the return of volume. In May, pricing supported a business whose shipments were still declining; the second-half forecast rested on converting an expanding order book. Q3 delivers that conversion across both major groups. The earnings beat is modest, but its operating content answers more of the standing thesis than the size of the surprise suggests.
| Metric | Q3 FY26 actual | Consensus | Beat / miss |
|---|---|---|---|
| Net sales | $4,873M | $4.79B–$4.80B | Beat ~1.5%–1.7% |
| Adjusted diluted EPS | $1.71 | $1.68 | +$0.03 / +1.8% |
| Metric | Emerson’s May Q3 guide | Actual | Result |
|---|---|---|---|
| Reported sales growth | ~5.5% | 7% | Above |
| Underlying sales growth | ~5% | 6% | Above |
| Adjusted segment EBITA margin | ~28% | 28.5% | ~50 bps above |
| Adjusted EPS | $1.65–$1.70 | $1.71 | $0.01 above high end |
| GAAP continuing EPS | $1.22–$1.27 | $1.28 | $0.01 above high end |
Year-over-year comparison
| $M except per-share data | Q3 FY25 | Q3 FY26 | Change |
|---|---|---|---|
| Net sales | 4,553 | 4,873 | +7.0% |
| Gross profit | 2,393 | 2,655 | +10.9% |
| Gross margin | 52.6% | 54.5% | +190 bps |
| SG&A | 1,266 | 1,343 | +6.1% |
| Other deductions, net | 298 | 311 | +4.4% |
| Net interest expense | 95 | 85 | −10.5% |
| Pretax earnings | 734 | 916 | +24.8% |
| Net earnings from continuing operations | 580 | 718 | +23.8% |
| GAAP diluted continuing EPS | $1.03 | $1.28 | +24.3% |
| Adjusted diluted EPS | $1.52 | $1.71 | +12.5% |
| Adjusted segment EBITA | 1,232 | 1,387 | +12.6% |
| Adjusted segment EBITA margin | 27.1% | 28.5% | +140 bps |
| Operating cash flow, continuing operations | 1,062 | 1,425 | +34.2% |
| Capital expenditures | 92 | 102 | +10.9% |
| Free cash flow | 970 | 1,323 | +36.4% |
Sequential comparison
| Metric | Q2 FY26 | Q3 FY26 | Change |
|---|---|---|---|
| Net sales | $4,562M | $4,873M | +6.8% |
| Gross margin | 53.1% | 54.5% | +140 bps |
| Pretax earnings | $793M | $916M | +15.5% |
| GAAP diluted EPS | $1.10 | $1.28 | +16.4% |
| Adjusted diluted EPS | $1.54 | $1.71 | +11.0% |
| Adjusted segment EBITA margin | 27.6% | 28.5% | +90 bps |
| Free cash flow | $694M | $1,323M | +90.6% |
| Net interest expense | $84M | $85M | +$1M |
Quality of the Beat
Revenue now contains real volume, and the adjusted earnings increase is operational. GAAP gross margin and cash have a separate $82M refund benefit; the company removes that benefit from adjusted earnings. Those are different improvements with different durability.
Revenue assessment. The 6% underlying increase consists of 3% price and 3% volume, with currency adding another point to reported growth. That is a meaningful change from Q2’s 0.5% underlying growth and negative volume. Better Middle East logistics helped, but Software & Systems also grew 11% and Sensors grew 7% underlying. The recovery extends beyond a single disruption reversing, which increases our confidence in a mid-single-digit FY27 sales forecast.
Margin assessment. Adjusted segment EBITA rose $155M on $320M of incremental sales, roughly 48% incremental margin. Volume, price/cost and productivity support the 2028 margin pillar. Gross margin is less impressive than its 190-basis-point increase suggests: removing the $82M refund leaves approximately 52.8%, only modestly above last year’s 52.6%. The segment EBITA improvement excludes the refund and is the stronger evidence of operating progress.
EPS assessment. Operations contributed $0.19 to the $0.19 adjusted EPS increase. Currency and share count added $0.04 together, offset by $0.03 of stock compensation and $0.01 of other items. This resolves the earlier concern that currency and acquisition-related comparisons were carrying the adjusted increase. GAAP continuing EPS includes $0.11 from tariff refunds; the adjusted reconciliation removes that gain while adding back $0.35 of amortization, $0.13 of restructuring, $0.05 of deal-related costs and $0.01 of discrete taxes. Restructuring remains a meaningful economic cost even as the operational trend improves.
Segment Performance
The five reported segments sit within three business groups. Software & Systems combines Control Systems & Software and Test & Measurement; Intelligent Devices combines Sensors and Final Control. The group rows below are subtotals.
| Segment / group | Q3 sales | Underlying growth | Adjusted EBITA | Margin | Margin YoY |
|---|---|---|---|---|---|
| Control Systems & Software | $1,199M | +7% | $391M | 32.6% | −260 bps |
| Test & Measurement | $445M | +23% | $132M | 29.6% | +720 bps |
| Software & Systems | $1,644M | +11% | $523M | 31.8% | −30 bps |
| Sensors | $1,091M | +7% | $323M | 29.7% | +420 bps |
| Final Control | $1,586M | +3% | $424M | 26.7% | +120 bps |
| Intelligent Devices | $2,677M | +5% | $747M | 27.9% | +240 bps |
| Safety & Productivity | $552M | +2% | $117M | 21.2% | +80 bps |
| Total | $4,873M | +6% | $1,387M | 28.5% | +140 bps |
Control Systems & Software
Sales grew 7% underlying, a substantial improvement from Q2’s 2% decline. Ovation sales rose 23%, and power demand increasingly reaches grid software as well as plant controls. Adjusted EBITA was essentially flat at $391M, however: the 260-basis-point margin decline shows that shipment growth and software economics do not move together every quarter. Renewal timing and lower-margin project mix weighed on the broader Software & Systems group.
Assessment: The revenue conversion pillar is now supported by actual shipments, while the software-quality pillar still depends on renewal timing and ACV. We accept the stronger sales outlook without extrapolating the group’s historical peak margin into the new project mix.
Test & Measurement
The NI business grew 23% underlying against a mid-teens Q3 expectation, and orders rose 19%, including 70% semiconductor order growth. Semiconductor sales across Emerson grew 53%. Validation and production testing are benefiting from RF, mixed-signal and AI-related investment; aerospace and defense also contributed. The segment’s adjusted EBITA rose from $81M to $132M, with margin reaching 29.6%.
Assessment: NI is delivering both growth and integration economics, strengthening Bull 3 beyond the prior quarter’s evidence. GAAP segment earnings turned positive at $11M despite $108M of amortization and $13M of restructuring-related adjustments. The acquisition’s accounting burden remains substantial, but the claim that operating gains cannot reach GAAP profit is weaker this quarter.
Sensors
Underlying sales rose 7% after a flat Q2, supported by power, LNG and project-shipment timing. Adjusted margin reached 29.7%, up 420 basis points against the prior year and 80 basis points sequentially.
Assessment: The improvement confirms that February’s margin weakness was not the start of a continuing demand deterioration. Timing contributed to Q3 shipments, so our FY27 forecast assumes continued growth at a less dramatic pace, with the existing installed base supporting profitability.
Final Control
Underlying sales returned to 3% growth, led by power and improving Middle East execution. Adjusted margin rose 120 basis points to 26.7%, although it fell from 27.2% in Q2. More greenfield activity brings lower-priced work into the mix. Restructuring and related costs reached $48M, versus $8M a year ago and $25M in Q2; GAAP segment earnings slipped from $351M to $349M.
Assessment: The segment supports the backlog-conversion case but tempers the margin conclusion. Rising demand can coexist with pressure from project mix and restructuring. The prior watch item on restructuring has become larger, and we continue to assess cash returns alongside adjusted profit.
Safety & Productivity
Underlying growth of 2% consisted of 4% pricing against a 2% volume decline. North American electrical and utility activity offset weaker European and automotive markets. Adjusted margin improved to 21.2%, while restructuring costs contributed to a decline in GAAP earnings to $93M from $103M.
Assessment: This remains a pricing-supported business rather than a source of the company’s volume acceleration. Its modest growth supports our forecast but gives little reason to raise the portfolio multiple.
Key KPIs
| Indicator | Q2 FY26 | Q3 FY26 | Investment significance |
|---|---|---|---|
| Underlying orders | +5% | +7% | Demand supports continued conversion |
| Backlog, excluding AspenTech | $8.2B | $8.2B (+7% YoY) | Stable sequentially as shipments accelerate |
| Book-to-bill | 1.07 | 1.0 | Revenue catches up with bookings |
| Project funnel | $11.2B | $12.4B | Longer-term opportunity expands |
| Quarterly funnel wins | ~$450M | ~$400M | No acceleration in award dollars established |
| Software ACV | $1.64B / +9% | $1.68B / +9% | 10%-plus exit target still ahead |
| Growth-vertical sales | +22% | +27% | Capex exposures outperform the company |
| Power sales | +23% | +37% | Portfolio-wide operating driver |
| Ovation orders | +41% | +31% | Strong demand against a larger base |
| Digital grid management ACV growth | +31% | +28% | Strong, though slower than Q2 |
| MRO share of sales | 65% | 65% | Recurring replacement demand stabilizes mix |
Key Topics & Management Commentary
Overall Management Tone: Management moved from defending a reduced second-half forecast to explaining delivered growth. Its confidence was supported by shipments and margin, while responses on software and Middle East normalization continued to depend on future milestones.
1. Backlog conversion changes the starting point for FY27
Backlog held at $8.2B as underlying revenue accelerated to 6% and book-to-bill reached 1.0. A flat backlog is constructive in this context: orders are replenishing an order book that is now producing faster sales. Intelligent Devices grew 5%, above the prior 4% Q3 plan, making the recovery broader than NI alone.
“Our second half underlying sales growth is accelerating as we lap the software contract renewal dynamic and execute project shipments from our backlog, which continues to grow year-over-year.”
— Michael Baughman, Chief Financial Officer
Assessment: Bull 2 moves from Neutral to Confirmed. We can now build FY27 from demonstrated volume rather than a deferred second-half promise. Continued order growth remains necessary because the same shipment improvement that validates the thesis consumes backlog.
2. Cash improves enough to narrow our forecast discount
Nine-month free cash flow is $2,618M, up $217M from $2,401M. Removing the $82M refund leaves $2,536M, or 5.6% growth. The operating working-capital cash outflow narrowed from $613M in the first half to $320M year to date, implying approximately $293M released in Q3. This supports the earlier explanation that inventory and project activity would turn into cash as shipments increased.
“Cash exceeded expectations due to good operational performance, along with the impact of tariff refunds and the timing of tax payments, which shifted from Q3 to Q4.”
— Michael Baughman, Chief Financial Officer
The refund explains about 38% of the nine-month cash increase, and the tax deferral adds an undisclosed benefit. The new ~$3.6B guide requires approximately $982M in Q4. That is a much smaller remaining requirement than the $2.2B–$2.3B second-half hurdle we emphasized in May, but it must absorb the deferred tax payments.
Assessment: Our prior below-guide cash estimate was too cautious for the operating progress now visible. We raise FY26 free cash flow to $3.55B from $3.35B–$3.50B, including the received refund but allowing a modest shortfall to management’s Q4 cash expectation. Bear 2 remains Emerging with substantially lower severity; the tax settlement makes one more quarter of confirmation valuable.
3. Power extends visibility, with a different margin mix ahead
Power revenue grew 37%, and its project funnel increased $450M sequentially to $3B. The current revenue base is still largely fleet modernization; gas-fired additions, behind-the-meter generation and grid investment broaden the next phase. These projects reach controls, software, sensors and valves, validating the integrated portfolio rationale.
“Power to date, which has been extremely strong, has been mostly fleet modernizations.”
— Ram Krishnan, Chief Operating Officer
The $12.4B total project funnel is predominantly greenfield, while replacement and modernization work commands better pricing. That makes the funnel attractive for growth without making every incremental dollar equally profitable. The move toward new capacity is consistent with our FY27 margin improvement assumption, but it argues against applying Q3’s 48% incremental margin indefinitely.
Assessment: Bull 1 strengthens because the demand extends beyond a single modernization cycle. Our forecast captures sustained growth and moderate margin expansion, with lower-priced greenfield mix restraining the profit increment.
4. Semiconductor testing strengthens the NI deal defense
Emerson raised full-year Test & Measurement underlying growth to about 14% after Q3’s 23% increase. A 19% order increase supports further expansion even as Q4 growth slows to roughly 10% against a harder comparison. Asked about a peer’s concern that testing growth could slow in 2027, management distinguished Emerson’s production and validation applications from laboratory testing. Different applications can have different cycle lengths.
“Look, we're not going to obviously guide into '27. You can certainly read into the tremendous order momentum that we have in the semiconductor business within T&M today. But I will highlight that there is a differentiation in growth in the applications from the laboratory, where I think the period that you're referencing largely plays to the validation and production side where we largely play. And that has a different dynamic on growth and in the cycle as well. And so at this point in time, I continue to be relatively robust on semiconductors through 2027.”
— Lal Karsanbhai, President and Chief Executive Officer
Assessment: The order book supports continued earnings contribution from NI, not another year at Q3’s growth rate. Our FY27 company forecast assumes a moderation in testing growth, which protects the estimate against a normalization in semiconductor equipment spending without dismissing the current strength.
5. Software still has a fourth-quarter promise to deliver
Software ACV rose to $1.68B, but growth remained 9% for a third consecutive quarter. Digital grid management ACV grew 28%, so excellent performance in one application has not yet lifted the aggregate beyond the prior 10%-plus goal. Control Systems & Software is now guided to 3.5% full-year underlying growth, including approximately three points of renewal headwind.
“So ACV 9%, and I think we feel pretty good about exiting the year at 10-plus percent on ACV. So I think from a software perspective, the dynamics of -- if your specific question was the renewal dynamic, that certainly reverses in the fourth quarter, and you'll see that reflected in the numbers in the fourth quarter.”
— Ram Krishnan, Chief Operating Officer
The May case anticipated a second-half renewal recovery; the current commitment locates the reversal in Q4. The appointment of a Chief Technology and AI Officer, effective August 15, adds organizational focus, but the call supplies no new quantified revenue contribution from AI products. The commercial test remains contract value and renewal economics.
Assessment: We retain the renewal recovery inside the Q4 earnings forecast and do not add a separate AI revenue premium. The ACV upgrade signpost remains unmet; better hardware and testing results cannot substitute for it.
6. Geographic concentration eases, while Middle East timing stays conditional
| Underlying sales growth | Q2 FY26 | Q3 FY26 |
|---|---|---|
| United States | +9% | +10% |
| Europe | −4% | −1% |
| China | −9% | −3% |
| Asia, Middle East & Africa | −5% | +8% |
International underlying sales grew 4% in Q3, a useful counterweight to the strong U.S. business. The Middle East annual revenue impact is now estimated at $100M versus roughly $150M in May, with $25M of drag in Q3 and a similar amount expected in Q4. Field service is back to pre-conflict levels, while customer operating capacity remains around 75%.
“Our field service engineers are now operating at pre-conflict levels, but customer operational capacity remains approximately 75%.”
— Lal Karsanbhai, President and Chief Executive Officer
Assessment: Bear 3 moves from Materializing to Emerging: the geographic base is broadening rather than continuing to narrow. This is a reduction in an existing risk, not proof of a synchronized global recovery. Our FY27 growth estimate does not require immediate normalization of Gulf export routes or a large China chemical rebound.
7. Productivity gains come with higher restructuring costs
Adjusted segment margin of 28.5% exceeds both the Q3 plan and the prior implied second-half requirement of approximately 28.3%. Price/cost and cost reductions more than offset inflation. At the same time, total restructuring and related costs rose to $99M from $41M, and the full-year EPS add-back increased to approximately $0.24 from $0.18 in May.
“Margin expansion exceeded expectations due to better volume than expected and favorable segment mix. Price cost and cost reductions more than offset inflation.”
— Michael Baughman, Chief Financial Officer
Assessment: Bull 4 remains Confirmed, but the path to 30% must be evaluated alongside the spending required to get there. The larger restructuring adjustment explains why we attach more weight to sustained cash conversion than to a single quarter’s adjusted margin peak.
8. Leverage becomes less of an earnings obstacle
Net debt fell to $10.93B from $11.57B at March 31. Gross debt was $13.11B, including $5.59B current, against $2.18B cash. Interest expense of $85M is still substantial but now below the $95M prior-year quarter; the financing step-up has been lapped. Share repurchases reached $898M year to date, leaving approximately $102M against the $1B annual plan.
“There are no changes to our planned return of approximately $2.2 billion to shareholders through $1.2 billion in dividends and $1 billion of share repurchase.”
— Michael Baughman, Chief Financial Officer
Assessment: Bear 1 remains Emerging rather than Materializing. Earnings can now grow without a new acquisition-financing headwind absorbing the increase. Continued deleveraging would create capacity for shareholder returns, but we assume only a modest interest reduction and a small share-count benefit in FY27.
Guidance & Outlook
| FY26 metric | May guide | August guide | Change |
|---|---|---|---|
| Reported sales growth | ~4.5% | ~5% | +50 bps |
| Underlying sales growth | ~3% | ~3.5% | +50 bps |
| Adjusted segment EBITA margin | ~28% | ~28% | Maintained |
| Adjusted diluted EPS | $6.45–$6.55 | ~$6.55 | Prior high end; +$0.05 vs midpoint |
| GAAP diluted EPS | $4.79–$4.89 | ~$4.89 | Prior high end |
| Operating cash flow | $4.0B–$4.1B | ~$4.1B | Prior high end |
| Free cash flow | $3.5B–$3.6B | ~$3.6B | Prior high end |
| Share repurchases | ~$1B | ~$1B | Maintained |
| Q4 FY26 metric | New guide | Implication |
|---|---|---|
| Reported / underlying sales growth | ~5% / ~5% | Approximately $5.1B sales |
| Software & Systems underlying growth | ~10% | Both controls/software and testing at ~10% |
| Intelligent Devices underlying growth | ~3% | Moderation from Q3’s 5% |
| Safety & Productivity underlying growth | ~1% | Limited volume recovery |
| Adjusted segment EBITA margin | ~28.5% | Holds Q3’s rate |
| Adjusted diluted EPS | ~$1.85 | About 8% sequential growth |
| GAAP diluted EPS | ~$1.45 | About 13% sequential growth |
The remaining earnings bridge. Nine-month adjusted EPS of $4.71 plus approximately $1.85 in Q4 gives $6.56, consistent with the approximate $6.55 annual guide. The Q4 plan includes the renewal reversal and continued backlog shipments, but it does not require the company to repeat Q3’s 23% testing growth. Sales of about $5.1B imply a mid-single-digit sequential increase; the guided 28.5% segment margin keeps the full year close to 28%.
The scope of the raise. Management has moved to the old high end of its EPS and cash ranges. That is stronger conviction in the year, not a new earnings trajectory far above the original plan. The $82M cash refund is larger than the $50M increase from the old cash-guide midpoint, so the revised headline alone does not establish a higher recurring full-year cash expectation. Our estimate improvement comes from the actual working-capital recovery as well as the refund.
Analyst Q&A Highlights
Does a larger funnel mean slower conversion?
The question tested whether the expanding opportunity set merely extends delivery dates. Management described consistent award timing and a three-to-four-year funnel, with quarterly wins still around $400M.
Q: “The funnel movement is quite intriguing. Obviously, you gave some anecdotal color, the growth in LNG and power in the funnel. Just also wondering, is this even increasingly long-dated sort of project activity? In other words, kind of conversion of funnel to proposal to order. Anything changing there of note?”
— Jeffrey Sprague, Vertical Research
A: “No, not really. Look, we continue to see about the same level of awards in the quarter. If you recall, we won approximately $400 million. That's very similar to the amount that we reported in the second quarter as well. So the timing of financing and awards continues to move relatively consistently over time.”
— Lal Karsanbhai, President and Chief Executive Officer
Assessment: The answer supports visibility, not accelerating awards. We give the larger funnel credit for sustaining future growth while using booked orders and shipments to determine the near-term estimate.
How far do power bookings extend?
The exchange put a specific date on Ovation’s visibility. The answer reaches beyond our FY27 earnings period, although booked projects can still move in time.
Q: “The Ovation orders, I think you said, up 31%. I think you said, Mike, up 31%. But what kind of lead times are you looking at now? Are you taking orders well into, I would imagine, well into maybe even the back half of '27 at this point?”
— Scott Davis, Melius Research
A: “That's exactly right, Scott. We're sitting in the fourth quarter of '27, reaching into '28 at this point.”
— Lal Karsanbhai, President and Chief Executive Officer
Assessment: This is concrete support for carrying the power pillar into FY27. It is not a guarantee of the company-wide growth rate: testing, MRO and other regions operate on different demand cycles.
Does Middle East repair work create an immediate growth tailwind?
The question challenged the coexistence of reconstruction activity and a continuing revenue drag. Management declined to assume that the drag disappears at the start of FY27.
Q: “Look, just a question on Middle East. I think you said repair construction is underway, $25 million headwind in third quarter, fourth quarter to be similar. So the question is, so Middle East rebuild opportunity is larger today and starting, but still in that drag in the fourth quarter. Does it flip to a tailwind in the first quarter of '27?”
— Andrew Obin, Bank of America
A: “It's a good question. It really -- in the status quo, in terms of an on-off situation of the Strait of Hormuz challenges with getting product out of the Gulf, I think that's going to continue to be touch and go. Maybe conditions improve, and that gets a little bit better for us as we go through the second half of 2027. But right now, as we're planning, I would expect to be realistic that the -- certainly the fourth quarter and perhaps into the first quarter of this -- of our fiscal year, the conditions remain relatively the same.”
— Lal Karsanbhai, President and Chief Executive Officer
Assessment: The response limits the near-term recovery case. Repair demand and export constraints can coexist, so our forecast does not add the earlier $100M rebuild estimate as an automatic incremental FY27 revenue line.
Are high utilization rates delaying maintenance?
Management distinguished daily replacement demand from planned shutdown work. Strong plant utilization supports parts demand but can postpone larger maintenance events.
Q: “Well, maybe just your thoughts on MRO in general. I think you've highlighted it today as stable. But I think generally, it's seen, it's been pretty strong across you and your peers. So what are you seeing there is that, I assume, led by North America, but obviously, we're running facilities pretty hard. So what are you seeing going forward here?”
— Andrew Kaplowitz, Citigroup
A: “There continues to be spend on replacement. We have seen, and I think to your point, we have seen some delays in shutdown turnaround activity because exactly, facilities are being run relatively hard right now. So that -- we'll see how the fall season ultimately shapes up there, which will -- would may have an impact to MRO activity, but day-to-day MRO continues to be very strong for us across the every -- just about every region and every business.”
— Lal Karsanbhai, President and Chief Executive Officer
Assessment: The 65% MRO base provides resilience but does not eliminate quarterly timing. We treat delayed turnarounds as a phasing risk and retain moderate growth, rather than converting high utilization into an unsupported maintenance-spending surge.
Can Intelligent Devices recover without a large China rebound?
The challenge asked whether the group could return to historical double-digit growth without a large China rebound. Management answered affirmatively, citing orders and the eventual release of Middle East shipments, while framing sustainable growth at 3–6%.
Q: “If you guys could expand on the China comment. First off, -- was it -- did it stabilize in the quarter? Is it as expected? And then within Intelligent Devices, I wonder, can that growth rate get back to kind of historical peak levels without China really picking up? Or do you think there's enough growth in North America and elsewhere to more than offset it and get back to like types of growth we've seen in the past in the double digits in that segment?”
— Andrew Buscaglia, BNP Paribas
A: “So on Intelligent Devices, the answer is, absolutely. I think as -- if you looked at orders performance as a leading indicator, I think you'll start seeing that. Now a majority of the sales impact in the Middle East is in our Intelligent [ Devices ] business. So you'll see that obviously suppress the growth rate so far, but that will unlock in Q4 and into next year. So yes, no concerns about the return to growth of Intelligent Devices. Now our guide there is 3% to 6%. I mean we've had years of double digits, but Intelligent Devices are in our long-range framework, our Systems & Software business is a 6% to 9% growth business, which includes Control Systems and T&M and Intelligent Devices in 3% to 6%. So we feel very good in that framework.”
— Ram Krishnan, Chief Operating Officer
Assessment: Management is confident that orders and improving Middle East execution can offset weak China demand, which supports our recovery case. Its affirmative answer leaves room for above-framework growth in a strong year, but the 3–6% long-range range is not a numerical FY27 commitment. We retain mid-single-digit company growth and treat a larger China rebound as upside.
Will greenfield projects command the same pricing?
The question tested both the composition of the funnel and whether new orders receive pricing comparable to the current 3% contribution. Management gave a relative pricing hierarchy, not a quantified price forecast.
Q: “Maybe just to ask the greenfield question in a different way that was asked earlier. Ram, I appreciate the comments on the power and the semi markets that you made earlier. Is there a way to help frame how much of the total project funnel today is for new greenfield versus brownfield? And I'm just curious if you're seeing any kind of material differential in pricing for those new orders versus the 3% you [ recorded ] this past quarter?”
— Kenneth Newman, KeyBanc Capital Markets
A: “I mean the pricing, obviously, we get better pricing on the modernizations than we do typically on greenfield, and we get better pricing on MRO than brownfield. So that's somewhat consistent with how we've always kind of positioned it. But most of the $12.4 billion, I would say, venture to say, we look at that as greenfield.”
— Ram Krishnan, Chief Operating Officer
Assessment: The trade-off is economically important: more greenfield work improves duration while diluting pricing mix. Our 38% FY27 incremental adjusted EBITA assumption is below Q3’s realized segment increment, allowing volume leverage to coexist with this mix pressure.
What They’re NOT Saying
- The amount of tax cash shifted into Q4. The deferral explains part of Q3’s cash strength, but its size was not disclosed. This is the principal uncertainty behind our modest discount to the ~$3.6B free-cash-flow guide.
- A numerical bridge from 9% ACV growth to 10%-plus. Management reaffirmed the exit goal and the renewal reversal without sizing the new-contract contribution required. A stronger controls shipment quarter does not settle the recurring-software growth question.
- The payback on larger restructuring programs. Final Control’s $48M adjustment and the higher FY26 restructuring outlook were not accompanied by a specific savings/payback bridge. That limits how much permanent margin credit we assign to the expense.
- A revised total for Middle East rebuild work or remaining tariff refunds. The previous repair opportunity remains distinct from larger capacity reconstruction, and further refunds are uncertain. Neither receives a separate uplift in our base earnings forecast.
Market Reaction
- Pre-print setup: EMR closed August 4 at $158.84, up 19.7% year to date and 14.2% over the trailing 30-day comparison. The S&P 500 was up 13.0% year to date.
- Initial response: Shares weakened in after-hours trading despite the beat and outlook increase.
- August 5 reaction session: EMR opened at $157.27, a 1.0% gap down, traded between $155.50 and $164.87, and closed at $162.47, up $3.63 or 2.3%.
- Participation and benchmark: Volume was 5.3M shares against a 2.8M trailing average, or 1.9 times normal. The S&P 500 fell 0.2% on the session.
The recovery from an opening decline is consistent with investors giving more weight to delivered volume, margin and cash as they evaluated the print. The company outperformed the index by about 2.5 percentage points, though that comparison does not isolate a causal earnings effect. The operating improvement provides a stronger explanation for the positive close than the small increase in the annual EPS midpoint alone.
The pre-print rally matters more for our rating than the direction of a single session. EMR entered earnings after a 14.2% increase over the trailing month and finished above our prior fair-value range. The business has met much of the condition we set in May; the stock has also moved far enough that meeting that condition no longer supplies the prospective return it would have offered at the earlier price.
Street Perspective
Debate: Has the second-half conversion risk been retired?
Bull view: Revenue, adjusted margin and free cash flow all exceeded the company’s expectations, while orders remained strong. The backlog story now has reported volume behind it.
Bear view: Cash benefited from a refund and tax timing, software ACV remains below the year-end objective, and Q4 still contains the renewal reversal. The improvement does not remove all of the year’s execution risk.
Our take: The bulls have the stronger operating argument. We confirm the backlog-conversion pillar and raise cash estimates. The remaining uncertainties justify a modest forecast cushion rather than retaining the large cash skepticism of the May report.
Debate: Does power and testing strength justify a larger premium?
Bull view: Multi-year power commitments and strong production-test orders give the transformed portfolio better visibility than a conventional short-cycle industrial business. Lower interest drag allows more of the operating gains to reach EPS.
Bear view: Testing is cyclical, greenfield projects have weaker pricing than maintenance work, and restructuring remains expensive. Strong end markets do not automatically produce software-like economics across the portfolio.
Our take: A premium is justified, but it belongs on a realistic next-year earnings estimate. Our 23–24 times FY27 range recognizes visibility and the MRO base without assuming every project inherits the highest-margin software characteristics.
Debate: Does a better quarter make the shares an Outperform?
Bull view: Q3 has supplied the revenue-and-cash evidence previously required for an upgrade, and geographic weakness is easing. Waiting for every final signpost risks missing a continuing capex cycle.
Bear view: The stock already discounts improved earnings. At nearly 25 times FY26 adjusted EPS, another good quarter may mainly validate the current price.
Our take: The operational upgrade condition matters and has largely been met. It changes our estimates and fair value. At the current price, however, the central twelve-month return remains about 5.5%, offering no clear excess over our 6–8% working S&P 500 return assumption. Hold reflects that prospective comparison.
Our Estimates & Valuation
| Item | Prior analyst view | Current analyst view | Reason |
|---|---|---|---|
| FY26 underlying growth | ~3% | ~3.5% | Q3 volume and reduced Middle East drag |
| FY26 reported sales | ~$18.8B | ~$18.9B | Approximately 5% growth on $18,016M FY25 |
| FY26 adjusted segment margin | 27.9%–28.1% | ~28% | Q3 above plan; Q4 ~28.5% |
| FY26 adjusted EPS | $6.45–$6.55 | ~$6.55 | Move to former high end |
| FY26 free cash flow | $3.35B–$3.50B | ~$3.55B | Working-capital recovery; includes $82M refund |
| Q4 free cash flow | n/a | ~$0.93B | Estimate less nine-month $2.618B |
| FY27 reported sales | n/a | ~$19.96B / +5.5% | Backlog, power and moderate testing growth |
| FY27 adjusted EPS | n/a | ~$7.20 | Operating growth plus modest financing/tax benefits |
The FY27 earnings bridge
Our $7.20 forecast starts from FY26 adjusted EPS of $6.55. We expect about 5.5% revenue growth, taking sales from approximately $18.92B to $19.96B. Applying a 38% incremental adjusted EBITA margin after corporate costs to roughly $1.04B of additional revenue yields approximately $395M of incremental pretax profit, or about $0.55 per share after a 21.5% tax rate and roughly 560M shares. This assumes continued productivity and volume leverage, moderated by greenfield mix and slower testing growth.
| FY26-to-FY27 adjusted EPS bridge | Per share | Analyst assumption |
|---|---|---|
| FY26 estimate | $6.55 | Current-year guide |
| Operating growth | +$0.55 | ~5.5% sales growth; ~38% incremental adjusted EBITA |
| Lower interest | +$0.04 | ~$29M reduction in annual net interest expense |
| Share count | +$0.04 | ~560M to ~557M diluted shares |
| Tax | +$0.02 | Small benefit as the FY26 tax change laps |
| FY27 estimate | ~$7.20 | ~10% EPS growth; rounded components |
These are our estimates, not FY27 company guidance. No incremental acquisition, further tariff refund or separately priced AI revenue is required. A one-percentage-point change in sales growth changes EPS by roughly $0.10 under the same incremental-margin assumption. A 50-basis-point change in annual adjusted operating margin changes EPS by about $0.14, illustrating why project mix matters as the funnel converts.
A consistent twelve-month valuation
We value FY27 adjusted EPS of $7.20 at 23–24 times, producing $165.60–$172.80, rounded to a $166–$173 fair-value range for August 2027. The 23.5-times central case is $169.20. This multiple recognizes the 65% MRO base, demonstrated margin execution and multi-year power visibility, while allowing for cyclical testing demand, leverage and recurring restructuring costs. It is our valuation judgment rather than a company target.
The prior $148–$162 range did not specify a target multiple. The increase to the new range is principally a move from the earlier current-year valuation discussion to explicit FY27 earnings, not a claim that a $0.05 FY26 EPS revision alone creates an $11–$18 valuation gain. Holding our new 23.5-times convention constant, moving from $6.55 to $7.20 adds about $15.28 per share; the $0.05 change in FY26 earnings adds only about $1.18. Better conversion evidence supports carrying that growth forward.
At the $162.47 reaction close, EMR trades at 24.8 times FY26 adjusted EPS and 22.6 times our FY27 estimate. Assuming the current $0.555 quarterly dividend continues, $2.22 of annual dividends raises total return to the central value to about 5.5%; the unrounded fair-value range implies about 3.3%–7.7%. That is broadly comparable with, and slightly below at the central case, our 6–8% S&P 500 total-return assumption over the same horizon. It does not offer a clear margin for outperformance.
| Twelve-month case | FY27 adjusted EPS | P/E | Value | Total return incl. $2.22 dividend |
|---|---|---|---|---|
| Downside | $6.65 | 20x | $133.00 | −16.8% |
| Central | $7.20 | 23.5x | $169.20 | +5.5% |
| Upside | $7.60 | 25x | $190.00 | +18.3% |
The downside assumes only about 2% sales growth, weaker incremental profit as testing and export logistics disappoint, and a lower multiple as the growth premium contracts. Lowering sales growth from 5.5% to 2% removes roughly $0.35 of EPS; an additional $0.20 from margin and financing pressure brings the estimate toward $6.65. The upside requires approximately 7% sales growth, stronger margin conversion and confidence in software acceleration sufficient to support 25 times. These are sensitivities, not equally likely forecasts; the central operating path remains the most plausible.
Thesis Scorecard Post-Earnings
| Standing thesis point | Quarter’s verdict | Status and investment consequence |
|---|---|---|
| Bull 1: Power/LNG/near-shoring capex cycle | Confirmed | ON TRACK unchanged. Power +37%, $12.4B funnel and Ovation visibility strengthen the existing case. |
| Bull 2: Backlog converts to accelerating revenue | Confirmed; previously Neutral | ON TRACK unchanged. Underlying sales +6% with 3% volume and Intelligent Devices +5% meet the prior operating test. |
| Bull 3: Test & Measurement integration delivers | Confirmed | ON TRACK unchanged. Sales +23%, margin 29.6%, positive GAAP segment earnings; cyclical risk remains. |
| Bull 4: Path toward 30% adjusted segment margin by 2028 | Confirmed | ON TRACK unchanged. 28.5% exceeds the quarterly plan; greenfield mix and restructuring qualify the trajectory. |
| Bear 1: AspenTech leverage absorbs operating gains | Challenged this quarter | EMERGING unchanged. Net debt falls to $10.93B and interest declines YoY, though gross debt remains substantial. |
| Bear 2: Back-loaded FY26 guidance | Challenged, not fully resolved | EMERGING unchanged, lower severity. Volume delivered and cash improved; ~$0.98B Q4 cash, tax settlement and renewals remain. |
| Bear 3: Growth is narrowing geographically | Challenged | MATERIALIZING → EMERGING. International growth +4%; China and Europe remain negative but improve. |
Overall: The thesis is stronger. The formerly unproven conversion pillar is now confirmed, and the geographic and financing risks have eased. The outstanding software target and the quality of the final cash quarter are narrower questions than whether the second half would materialize at all.
Action: Maintain Hold, with conviction 6/10 and twelve-month fair value of $166–$173. The revenue-and-cash signpost from May has been substantially met and is reflected in higher estimates; the price has also advanced. An upgrade would require a more attractive prospective return, through a lower entry price or earnings evidence above our $7.20 FY27 base, with ACV clearing 10%-plus and durable cash conversion supporting that revision. Failure to deliver the roughly $982M Q4 cash requirement, another renewal delay, or a broader demand decline would challenge the base case and could prompt a downgrade.